Continuous Cardiac Monitoring.
Corsano Health B.V. advances healthcare by allowing continuous patient monitoring using big-data to generate insights for healthcare professionals. The Corsano brandname is derived from in corpore sano (in a healthy body).
Corsano’s real time research platform, enabled by the world’s most advanced smart bracelet for continuous monitoring of vital signs, offers un-restricted access to raw data for AI and ML development.
The Corsano Cardiowatch Bracelet is the most patient friendly medically certified wearable with ergonomic and aesthetic designs for continuous wear (also during sleep), Swiss quality, long battery life of 8-15 days. Corsano’s offering is the basis of telehealth, for continuous monitoring of patients in multiple disease areas: cardiovascular diseases, oncology, stress related diseases, recovery, etc. Smart analytics produce relevant data for timely detection of heart rhythm anomalies. The Corsano Cardiowatch 287 Bracelet is medically certified, both device and platform EU-MDR certified, FDA 510K Q4 2023.
Clinical evidence for multiple use cases. ISO13485 and EU-MDR certified
Built in close collaboration with clinical professionals.
Security & Privacy
Corsano is enabling clinical trials, in-hospital and remote patient care across the entire care continuum with our clinically validated and EU-MDR certified CardioWatch 287 platform (FDA pending).
Clinical Trials: Corsano is currently involved in 35 clinical trials – Cardiovascular, Oncology and Stress. Corsano’s medically certified wearables increase credibility of studies and prepare for medical digital therapies. Corsano’s involvement in important clinical trial research consortia accelerates the pace of medical research, enabling the discovery of new biomarkers and their clinical validation.
Real-time Remote Patient Monitoring: Corsano CardioWatch 287 can monitor up to 19 Vital Parameters in real-time while post-discharge programs often rely solely on episodic vitals (spot measurements). Healthcare providers can develop personalized treatment plans that address the unique needs of each patient. Corsano can provide patients with real-time feedback on their progress, which can help motivate them to adhere to their treatment plan. Remote care-at-home programs deliver improved clinical outcomes, lower costs and better patient experience: 38% reduction in cost of care; 70% reduction in readmissions; 50% improvement in patient mobility
In-Hospital Monitoring: This is the solution where data from CardioWatch is directly streamed to the gateway (no need for phone app) and transferred to the hospital IT system, enabling central monitoring of patients and improved quality of work for nurses. By providing nurses with real-time information about their patients’ conditions, central monitoring can help ensure that patients receive appropriate care, treatment, and medication at the right time, leading to better overall outcomes.
Corsano offers an API (Application Programming Interface) and SDK (Software Development Kit) to providers of remote patient monitoring platforms and researchers, which allows them to connect Corsano CardioWatch to their platform. The API and SDK enable to access the data collected by Corsano CardioWatch, including synching of raw PPG, ECG, ACC and BIOZ data.
Medical grade, multi-sensor, convenient Cardiowatch 287-2 bracelet for continuous monitoring of cardio-respiratory functions.
EU-MDR CE Certified
The Cardiowatch Bracelet is a wireless remote monitoring system intended for continuous collection of physiological data in healthcare and home settings. Cardiowatch 287 is a CE medical device certified under EU-MDR standards. This includes Pulse Rate, Heart Rate Variability (R-R intervals), ECG, SpO2, Respiration, Core Body Temperature, Activity and Sleep. Data is transmitted wirelessly from the device via the application or gateway to a health cloud where it is stored and made available for further analysis.
Corsano Cardiowatch can include the ability to notify healthcare professionals when physiological data fall outside selected parameters.
The high-quality patented interface enables the device to accurately measure the following vital parameters:
- Sleep (validated PPG-Based Sleep Staging – Jul. 2017)
- A-Fib (CE Class IIa Certified algorithm Preventicus – May 2018)
- Activity Type, Speed, Cadence (validated VSO ELAN – Nov. 2019)
- Heart Rate (validated CCN – Mar. 2021)
- RR intervals (validated CCN – Mar. 2021)
- Respiration Rate (validated Haaglanden Clinics – Jun. 2021)
- SPO2 (validated CMC – Jun. 2022)
- Core Body Temperature (validated GreenTeg – Mar. 2022)
- Blood Pressure (Reinier de Graaf – Mar. 2023)
- Activity (RadBoudMC – Apr. 2023)
- Cardiac Arrest (in validation RadBoudMC, ErasmusMC, AMC – Dec. 2024)
First, I wanted to let you and the Corsano team know how very impressed I am with your device. I’ve tried out more wearable sensors than most people, and the CW287-2B is, by far, my favorite and most valuable. Congratulations to your entire team for your vision and for delivering on that. I believe your technology will have a significant impact on improving health across the globe.
Prof. Steven Steinhubl, MD – Purdue University
Corsano has made “Cooperation” one of the core values upon which the company commits to base all its relationships. To be successful in business and life, a relationship has to be a two way street with give and take. At Corsano, we believe in cultivating good working relationships with our partners. We don’t limit ourselves to a select few, but always attempt to find the best possible partners. Corsano develops and manufactures medical wearables for research and continuous patient monitoring, that is our core business. Our open strategy is to connect CardioWatch to partner platforms and systems via APIs abd SDKs. We provide access to raw and processed data to partners enabling them to offer a variety of medical research and patient care services. As such, we deal with hospitals, CROs, associations and companies worldwide.
Large Research Projects
Corsano participates in Europe’s research and innovation challenges where we collaborate with researchers in consortia with partners. Corsano Health’s CardioWatch is the preferred choice to measure vital parameters, both for the acquisition of raw data up to 128Hz, as well as validation clinical trials. We offer co-development of new features and algorithms to increase success of consortia applications. Recently awarded projects:
Project for a validated, energetically autonomous module that harvests from any source of light through a novel microchip, the PMIC developed by Nowi. Narrow-Band IoT chip (NB-IoT) will be integrated into the module for ubiquitous connectivity.
Clinical validation of a comprehensive care solution (‘WATCH-IT’) enabling 24/7 monitoring of cardio-respiratory function in patients at risk of cardiovascular (CV) events. Collaboration with Preventicus, Oslo University Hospital (OUH) and University of Gothenburg (GU).
Innovative solution to improve recognition and implementation of resuscitation assistance for patients with Cardiac Arrest. Development project in colaboration with RadboudMC to recognize Cardiac Arrest with Cardiowatch 287 Bracelet and alert emergency services.